Ireland· IE-PA-EU/1/25/1998/001-003
Teizeild 1 mg/mL concentrate for solution for infusion
A teplizumab product containing teplizumab, registered in Ireland by Sanofi Winthrop Industrie. The same ATC class is registered in 13 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Teplizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC A10XX01 (teplizumab), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 9 of them publish a price we can compare per daily dose
Teplizumab · ATC A10XX01
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
HPRA (Ireland)- Active substance
- Teplizumab
- Manufacturer
- Sanofi Winthrop Industrie
- Country
- Ireland (IE)
- ATC code
- A10XX01
- ATC class
- Teplizumab
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/25/1998/001-003
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Teplizumab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTEIZEILDSanofi Winthrop Industrie, Gentilly
- SwitzerlandTeizeild 2 mg/2 mL, solution à diluer pour perfusionSanofi-Aventis (Suisse) SA
- FinlandTeizeildSanofi Winthrop Industrie
- IcelandTeizeildSanofi Winthrop Industrie
- NorwayTeizeildSanofi Winthrop Industrie
- PolandTeizeildSanofi Winthrop Industrie
- BelgiumTeizeild 1 mg/mlSanofi Winthrop Industrie
- SwedenTeizeild 1 mg/ml Koncentrat till infusionsvätska, lösningSanofi Winthrop Industrie
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Teizeild
- Liechtenstein · Teizeild
- Norway · Teizeild
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/125ca1b2-30b7-4214-bd00-3a61e859fc24 GET /v1/drugs/125ca1b2-30b7-4214-bd00-3a61e859fc24?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"A10XX01"
],
"strength": null,
"pa_number": "EU/1/25/1998/001-003",
"substances": [
"Teplizumab"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "08/01/2026",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about teplizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.